---
title: "Azetukalner (XEN1101) in Focal onset seizures: References"
description: "Reference list for the formulary evidence report on Azetukalner (XEN1101) in Focal onset seizures. 163 cited documents."
canonical: "https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/references"
published: "2026-09-21T21:41:53-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Azetukalner (XEN1101) in Focal onset seizures: References

<a id="references"></a>

## 5 References

1. [Al-aqeel et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8092477/)
2. [Ángel Calleja et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35904256/)
3. [Auvin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10836613/)
4. [Babar et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8127139/)
5. [Becker et al. (2025)](https://aesnet.org/abstractslisting/characterization-of-long-term-seizure-freedom-in-the-ongoing-open-label-extension-of-x-tole-potential-implications-for-future-clinical-practice)
6. [Begley and Durgin (2015)](https://pubmed.ncbi.nlm.nih.gov/26216617/)
7. [Ben-Menachem et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4955277/)
8. [Beniczky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169392/)
9. [Birbeck et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12027916/)
10. [Blair (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3420439/)
11. [Boccaletti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11633719/)
12. [Boleti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10813806/)
13. [Bonnett et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22377180/)
14. [Borghs et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10390911/)
15. [Bradley et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7390263/)
16. [Brandt et al. (2023)](https://aesnet.org/abstractslisting/long-term-quality-of-life-improvements-in-adults-with-focal-onset-seizures-treated-with-xen1101-in-an-ongoing-open-label-extension-of-a-phase-2b-study-x-tole)
17. [Bresnahan et al. (2019a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6953346/)
18. [Bresnahan et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6806021/)
19. [Bresnahan et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7059897/)
20. [Bresnahan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8919456/)
21. [Bresnahan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10103545/)
22. [Brigo and Lattanzi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11292785/)
23. [Brigo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7389315/)
24. [Brodie et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3348850/)
25. [Brook et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6306097/)
26. [CADTH (2023)](https://www.ncbi.nlm.nih.gov/books/NBK600011/)
27. [CDC (2024)](https://www.cdc.gov/epilepsy/about/index.html)
28. [Cereghino et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10908898/)
29. [Cervenka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8610544/)
30. [Chang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8218144/)
31. [Chen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885858/)
32. [Chen et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10915785/)
33. [Chung et al. (2010a)](https://pubmed.ncbi.nlm.nih.gov/20132285/)
34. [Chung et al. (2010b)](https://pubmed.ncbi.nlm.nih.gov/21090838/)
35. [Chung et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7357293/)
36. [ClinicalTrials.gov NCT03340220](https://clinicaltrials.gov/study/NCT03340220)
37. [ClinicalTrials.gov NCT03468725](https://clinicaltrials.gov/study/NCT03468725)
38. [ClinicalTrials.gov NCT03796962](https://clinicaltrials.gov/study/NCT03796962)
39. [ClinicalTrials.gov NCT04952467](https://clinicaltrials.gov/study/NCT04952467)
40. [ClinicalTrials.gov NCT05614063](https://clinicaltrials.gov/study/NCT05614063)
41. [ClinicalTrials.gov NCT05716100](https://clinicaltrials.gov/study/NCT05716100)
42. [ClinicalTrials.gov NCT05718817](https://clinicaltrials.gov/study/NCT05718817)
43. [Czapińska-Ciepiela et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11294404/)
44. [EMA (2018)](https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt)
45. [Engel et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12601090/)
46. [Engel et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4821633/)
47. [Faught et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18565827/)
48. [FDA (2013)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022345s006lbl.pdf)
49. [FDA (2018)](https://www.fda.gov/media/110916/download)
50. [Fiest et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3589287/)
51. [Fiest et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27986877/)
52. [Fisher et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20331461/)
53. [Fisher et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24730690/)
54. [Fisher et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28276060/)
55. [French et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3413761/)
56. [French et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22905857/)
57. [French et al. (2021)](https://aesnet.org/abstractslisting/phase-2b-efficacy-and-safety-of-xen1101--a-novel-potassium-channel-modulator--in-adults-with-focal-epilepsy-(x-tole))
58. [French et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10562989/)
59. [French et al. (2024)](https://www.neurology.org/doi/10.1212/WNL.0000000000208587)
60. [French et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014913/)
61. [French et al. (2025b)](https://aesnet.org/abstractslisting/long-term-safety-and-efficacy-of-azetukalner-a-novel-potent-kv7-potassium-channel-opener-in-adults-with-focal-epilepsy-42-month-interim-analysis-of-the-ongoing-7-year-x-tole-open-label-extension)
62. [GBD 2016 Epilepsy Collaborators (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6416168/)
63. [Glauser et al. (2013)](https://www.ilae.org/files/ilaeGuideline/Guidelines-epilepsia-12074-2013.pdf)
64. [Greene and Hoshi (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5243414/)
65. [Gupta et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5719850/)
66. [Halloush et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12582735/)
67. [Handforth et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9674777/)
68. [Harden et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5486432/)
69. [Hermann et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8900353/)
70. [Hitiris et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17628429/)
71. [Hu et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39841033/)
72. [Ioannou et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/)
73. [Javarayee et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39306895/)
74. [Jehi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9562030/)
75. [Johannessen and Landmark (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3001218/)
76. [Josephson et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742541/)
77. [Joshi et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6891831/)
78. [Kanner et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145382/)
79. [Kanner et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145395/)
80. [Kanner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10074468/)
81. [Karnes et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7831382/)
82. [Karoly et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31471901/)
83. [Kenney et al. (2022)](https://aesnet.org/abstractslisting/rapid-onset-of-efficacy-of-xen1101--a-novel-potassium-channel-opener--in-adults-with-focal-epilepsy--results-from-a-phase-2b-study-(x-tole))
84. [Klein et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26471380/)
85. [Kobau et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11034729/)
86. [Krauss et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22517103/)
87. [Krauss et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31734103/)
88. [Kwan and Brodie (2000)](https://pubmed.ncbi.nlm.nih.gov/10660394/)
89. [Kwan and Brodie (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11921996/)
90. [Kwan et al. (2010)](https://www.ilae.org/files/ilaeGuideline/Definition-of-Drug-Resistant-Epilepsy-2009-1528-1167.2009.02397.pdf)
91. [Labate et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12255636/)
92. [Lado et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10962912/)
93. [Laskier et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36625423/)
94. [Lattanzi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8843918/)
95. [Lattanzi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38571335/)
96. [Lattanzi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12291020/)
97. [Lee et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34155568/)
98. [Lévesque et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7052840/)
99. [Li et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40751693/)
100. [Liu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5839310/)
101. [Löscher et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8408078/)
102. [Marson et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8047799/)
103. [Martins (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13510719/)
104. [Mbizvo et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7387854/)
105. [Medicaid.gov National Average Drug Acquisition Cost (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions%5B0%5D%5Bproperty%5D=ndc_description&conditions%5B0%5D%5Boperator%5D=in&conditions%5B0%5D%5Bvalue%5D%5B%5D=XCOPRI%20200%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=BRIVIACT%20100%20MG%20TABLET&conditions%5B0%5D%5Bvalue%5D%5B%5D=FYCOMPA%2012%20MG%20TABLET&conditions%5B1%5D%5Bproperty%5D=as_of_date&conditions%5B1%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bvalue%5D=2026-09-16&limit=10&properties%5B%5D=ndc_description&properties%5B%5D=ndc&properties%5B%5D=nadac_per_unit&properties%5B%5D=pricing_unit&properties%5B%5D=effective_date&properties%5B%5D=as_of_date)
106. [Mesraoua et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12113856/)
107. [MHRA (2025)](https://www.gov.uk/guidance/valproate-reproductive-risks)
108. [Morrell et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21917777/)
109. [Morris et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3854750/)
110. [Moura et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10969856/)
111. [Nair et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7538230/)
112. [Narducci et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12011995/)
113. [NICE guideline NG217 non-pharmacological treatments (2022)](https://www.nice.org.uk/guidance/ng217/chapter/8-Non-pharmacological-treatments)
114. [NICE guideline NG217 principles of treatment, safety monitoring and withdrawal (2022)](https://www.nice.org.uk/guidance/ng217/chapter/4-Principles-of-treatment-safety-monitoring-and-withdrawal)
115. [NICE guideline NG217 referral to tertiary specialist services (2022)](https://www.nice.org.uk/guidance/ng217/chapter/3-Referral-to-tertiary-specialist-services)
116. [NICE guideline NG217 terms used in this guideline (2022)](https://www.nice.org.uk/guidance/ng217/chapter/Terms-used-in-this-guideline)
117. [NICE guideline NG217 treating epileptic seizures (2022)](https://www.nice.org.uk/guidance/ng217/chapter/5-Treating-epileptic-seizures-in-children-young-people-and-adults)
118. [NICE technology appraisal guidance TA753 information about cenobamate (2021)](https://www.nice.org.uk/guidance/ta753/chapter/2-Information-about-cenobamate)
119. [NICE technology appraisal guidance TA753 recommendations (2021)](https://www.nice.org.uk/guidance/ta753/chapter/1-Recommendations)
120. [Panebianco et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7083514/)
121. [Panebianco et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8962962/)
122. [Paoletti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12063500/)
123. [Perucca and Taglialatela (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11850491/)
124. [Pharmaceutical Technology (2024)](https://www.pharmaceutical-technology.com/data-insights/azetukalner-xenon-pharmaceuticals-net-present-value/)
125. [Phillips et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5847474/)
126. [Porter et al. (2023)](https://aesnet.org/abstractslisting/the-impact-of-disease-severity-on-responder-rates-in-a-phase-2b-study-of-xen1101-a-potent-selective-potassium-channel-opener-in-adults-with-focal-epilepsy-x-tole)
127. [Premoli et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6856596/)
128. [Rajadhyaksha et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12514382/)
129. [Rosendahl et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13330554/)
130. [Rudkowska et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13509782/)
131. [Salanova et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4352097/)
132. [Salanova et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33830503/)
133. [Sarmast et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7575300/)
134. [Scheffer et al. (2017)](https://www.epilepsydiagnosis.org/doc/Scheffer_et_al-2017-Epilepsia.pdf)
135. [Scott et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28470748/)
136. [Semah et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9818842/)
137. [Shah et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4104618/)
138. [Shorvon et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10999557/)
139. [Singh and Carson (2024)](https://www.ncbi.nlm.nih.gov/books/NBK557579/)
140. [Sperling et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4354260/)
141. [Sperling et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9293007/)
142. [Sultana et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33722992/)
143. [Tatum et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8578031/)
144. [Thurman et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7004822/)
145. [Vismer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4448038/)
146. [Vonck et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40526429/)
147. [WHO Drug Information Recommended INN List 90 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl90.pdf)
148. [Wiebe et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11484687/)
149. [Wu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6551254/)
150. [Xenon Pharmaceuticals AAN 2026 data release (2026)](https://www.globenewswire.com/news-release/2026/04/19/3276673/33485/en/Xenon-Presents-Azetukalner-Phase-3-X-TOLE2-Study-Results-and-48-Month-Long-term-Data-in-Focal-Onset-Seizures-at-2026-AAN-Annual-Meeting.html)
151. [Xenon Pharmaceuticals AES 2025 data release (2025)](https://www.globenewswire.com/news-release/2025/12/05/3200741/0/en/Xenon-Showcases-New-48-Month-Azetukalner-OLE-Study-Data-in-Epilepsy-at-AES-2025.html)
152. [Xenon Pharmaceuticals EEC 2026 release (2026)](https://www.globenewswire.com/news-release/2026/08/26/3351670/33485/en/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational-polytherapy-potential-for-azetukalner-at-eec-2026.html)
153. [Xenon Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm)
154. [Xenon Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526338244/xene-20260630.htm)
155. [Xenon Pharmaceuticals J.P. Morgan Healthcare Conference release (2026)](https://www.globenewswire.com/news-release/2026/01/12/3216905/0/en/xenon-outlines-key-upcoming-milestones-at-the-2026-j-p-morgan-healthcare-conference.html)
156. [Xenon Pharmaceuticals NDA submission release (2026)](https://www.globenewswire.com/news-release/2026/09/17/3364364/33485/en/xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program.html)
157. [Xenon Pharmaceuticals neurology pipeline update (2023)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline-0)
158. [Xenon Pharmaceuticals OLE data release (2024)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-showcases-new-long-term-azetukalner-data-x-tole-ole-study)
159. [Xenon Pharmaceuticals Q2 2026 results release (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340663/33485/en/xenon-reports-q2-2026-financial-results-and-provides-business-update.html)
160. [Xenon Pharmaceuticals X-TOLE topline release (2021)](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-announces-positive-topline-results-phase)
161. [Xenon Pharmaceuticals X-TOLE2 topline release (2026)](https://www.globenewswire.com/news-release/2026/03/09/3251686/33485/en/Xenon-Announces-Positive-Topline-Data-from-Phase-3-X-TOLE2-Study-of-Azetukalner-in-Focal-Onset-Seizures-FOS.html)
162. [Zack and Kobau (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5687788/)
163. [Zhang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11296132/)

## Related pages
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Terms and abbreviations](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations.md)
- [Azetukalner (XEN1101): Focal onset seizures](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/executive-summary) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/executive-summary.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Product information and disease description](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/product-information-and-disease-description.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Clinical evidence](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/clinical-evidence.md)
- [Azetukalner (XEN1101) in Focal onset seizures: Economic information and modeling report](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economics) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economics.md)
- [Azetukalner (XEN1101) in Focal onset seizures: prevalence by geography](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/prevalence) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/prevalence.md)
- [Azetukalner (XEN1101) in Focal onset seizures: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/cost-effectiveness-analyses.md)
